HCW Biologics (HCWB) Price to Sales (2022 - 2026)

HCW Biologics (HCWB) has reported Price to Sales for 5 consecutive years, with 48.88 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales fell 72.75% year-over-year to 48.88; the trailing twelve-month figure through Jun 2026 stood at 35.87 (up 2442.79% YoY), and the FY2025 full-year result was 6.25, up 380.55% from the prior year.
• Price to Sales rose to 48.88 in Q2 2026 per HCWB's latest filing, from 12.56 in the prior quarter.
• Across five years, Price to Sales topped out at 16678.41 in Q1 2025 and bottomed at 5.22 in Q1 2022.
• Historically, Price to Sales has averaged 1020.54 across 5 years, with a median of 12.56 in 2025.
• The sharpest annual moves came in 2024 and 2025: Price to Sales sank 95.11% in 2024, then jumped 170241.93% in 2025.
• Over 5 years, Price to Sales stood at 8.54 in 2022, then plunged by 31.69% to 5.83 in 2023, then surged by 45.05% to 8.46 in 2024, then jumped by 48.41% to 12.56 in 2025, then jumped by 289.31% to 48.88 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 48.88, 12.56, and 106.75 for Q2 2026, Q4 2025, and Q3 2025 respectively.